PMID- 33058034
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210615
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Print)
IS  - 0770-3198 (Linking)
VI  - 40
IP  - 5
DP  - 2021 May
TI  - Investigating the safety and compliance of using csDMARDs in rheumatoid arthritis 
      treatment through face-to-face interviews: a cross-sectional study in China.
PG  - 1789-1798
LID - 10.1007/s10067-020-05458-w [doi]
AB  - Rheumatoid arthritis (RA) significantly impacts the health of Chinese patients. 
      Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are used 
      as the standard treatment for patients with RA. However, Chinese patients with RA 
      have reported poor compliance with csDMARDs. This study aims to better understand 
      the safety and compliance of using csDMARDs in RA treatment. Face-to-face 
      interviews were conducted by questionnaires on safety and compliance of csDMARDs 
      in 400 patients with RA and 100 rheumatologists from 13 cities in China. 
      Rheumatologists were from Tier 3 Class A hospitals with independent rheumatology 
      departments, who admitted more than 30 patients with RA per week. All patients 
      were diagnosed for > 3 months before the survey and had been treated with 
      csDMARDs for > 3 months. The incidence of adverse events (AEs) that attributed to 
      csDMARDs estimated by rheumatologists was lower than that reported by patients 
      for all four prescribed csDMARDs. Also, types of common AEs in rheumatologist's 
      perception differed from those in the patient's report. Only 86% (116/135) of 
      patients claimed they notified their rheumatologist about AEs, and 40.8% 
      (150/368) of patients did not strictly adhere to their prescribed treatment. 
      Reasons why patients were not compliant with their treatment, other than AEs, 
      included symptoms being less severe, travel, and busy working life/business 
      trips. This study revealed gaps in perceptions of csDMARDs-related AEs and 
      medication adherence between rheumatologists and patients. These findings 
      suggested adequate doctor-patient communications, and considerations of multiple 
      real-world situations may improve adherence in the treatment of RA patients. Key 
      Points * This study identified gaps in rheumatologists' perception of the 
      prevalence and type of AEs experienced by their patients, which could potentially 
      help them improve their patients' compliance with treatment.
FAU - Sun, Jiaying
AU  - Sun J
AUID- ORCID: 0000-0001-8786-612X
AD  - Department of Rheumatology and Immunology, First Affiliated Hospital of Harbin 
      Medical University, Harbin, 150086, Heilongjiang, China.
FAU - Dai, Siming
AU  - Dai S
AUID- ORCID: 0000-0002-7082-1432
AD  - Department of Rheumatology and Immunology, First Affiliated Hospital of Harbin 
      Medical University, Harbin, 150086, Heilongjiang, China.
FAU - Zhang, Ling
AU  - Zhang L
AD  - Shanghai Roche Pharmaceuticals Ltd., Shanghai, 201203, China.
FAU - Feng, Yajing
AU  - Feng Y
AD  - Shanghai Roche Pharmaceuticals Ltd., Shanghai, 201203, China.
FAU - Yu, Xin
AU  - Yu X
AUID- ORCID: 0000-0002-9764-9628
AD  - Shanghai Roche Pharmaceuticals Ltd., Shanghai, 201203, China.
FAU - Zhang, Zhiyi
AU  - Zhang Z
AUID- ORCID: 0000-0003-3951-3834
AD  - Department of Rheumatology and Immunology, First Affiliated Hospital of Harbin 
      Medical University, Harbin, 150086, Heilongjiang, China. zhangzhiyi2014@163.com.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Antirheumatic Agents)
SB  - IM
MH  - *Antirheumatic Agents/adverse effects
MH  - *Arthritis, Rheumatoid/drug therapy
MH  - China
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Rheumatologists
PMC - PMC8102276
OTO - NOTNLM
OT  - Adverse events
OT  - Compliance
OT  - Methotrexate
OT  - Questionnaire
OT  - Rheumatoid arthritis
OT  - csDMARD
COIS- Ling Zhang, Yajing Feng, and Xin Yu are employees of Shanghai Roche 
      Pharmaceuticals Ltd. The other authors declare that they have no known conflicts 
      of interest.
EDAT- 2020/10/16 06:00
MHDA- 2021/05/15 06:00
PMCR- 2020/10/15
CRDT- 2020/10/15 17:39
PHST- 2020/04/08 00:00 [received]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/09/06 00:00 [revised]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/10/15 17:39 [entrez]
PHST- 2020/10/15 00:00 [pmc-release]
AID - 10.1007/s10067-020-05458-w [pii]
AID - 5458 [pii]
AID - 10.1007/s10067-020-05458-w [doi]
PST - ppublish
SO  - Clin Rheumatol. 2021 May;40(5):1789-1798. doi: 10.1007/s10067-020-05458-w. Epub 
      2020 Oct 15.